مقایسه اثر ضد ویروسی پپتید لاکتوفرین شتری (CLF36) و داروهای نسل جدید بر علیه ویروس هپاتیت C

Reference

Abe Ki, Nozaki A, Tamura K et al. (2007) Tandem Repeats of Lactoferrin‐Derived Anti‐Hepatitis C Virus Peptide Enhance Antiviral Activity in Cultured Human Hepatocytes. Microbiol Immunol 51, 117-125.

 

Agarwal S, Mehrotra RJJC (2016) An overview of molecular docking. JSM chem 4, 1024-1028.

 

Azzam H, Goertz C, Fritts M et al. (2007) Natural products and chronic hepatitis C virus. Liver Int 27, 17-25.

 

Bolscher JG, Adão R, Nazmi K et al. (2009) Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie 91, 123-132.

 

Carugo O, Pongor S (2001) A normalized root‐mean‐spuare distance for comparing protein three‐dimensional structures. Protein Sci 10, 1470-1473.

 

Chikalov I, Yao P, Moshkov M et al. (2011) Learning probabilistic models of hydrogen bond stability from molecular dynamics simulation trajectories. BMC bioinformatics 12, 1-6.

 

Chung BK-S, Lee D-Y (2012) Computational codon optimization of synthetic gene for protein expression. BMC Syst Biol 6, 1-14.

 

De Clercq E (2007) The design of drugs for HIV and HCV. Nat Rev Drug Discov 6, 1001-1018.

 

Dial EJ, Lichtenberger LM (2002) Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 80, 113-117.

 

El-Fakharany EM, Sánchez L, Al-Mehdar HA et al. (2013) Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study. Virol J 10, 1-10.

 

Ferenci P (2012) Treatment of chronic hepatitis C–are interferons really necessary? Liver Int 32, 108-112.

 

Ghasemi Meymandi M, Mohammadabadi MR, Esmailizadeh AK (2015) Genetic variation of camels in the North of Kerman province using microsatellite markers. Anim Product Res 4 (1), 35-45 (In Persian).

 

Ghasemi Meymandi M, Mohammadabadi MR, Esmailzade A, Montazeri M (2016a) Assigning Individuals to the Camel Populations of North of Kerman Province Using Microsatellite Markers. Modern Genet J 11 (3), 329-335 (In Persian).

 

Ghasemi Meymandi M, Mohammadabadi MR, Montazeri M (2016b) Analysing Genetic Structure of Camelus dromedarius Using PCA and Hierarchical clustering methods. Agri Biotec J 8 (3), 83-96 (In Persian).

 

Gifford JL, Hunter HN, Vogel H (2005) Lactoferricin. Cell mol life sci 62, 2588-2598.

 

Hadizadeh M, Mohammadabadi MR, Niazi A, et al. (2013) Use of bioinformatics tools to study exon 2 of GDF9 gene in Tali and Beetal goats. Modern Genet J 8 (334), 283-288 (In Persian).

 

Hadizadeh M, Niazi A, Mohammad Abadi M, et al. (2014) Bioinformatics analysis of the BMP15 exon 2 in Tali and Beetal goats. Modern Genet J 9(1), 117-120 (In Persian).

 

Haney EF, Nazmi K, Bolscher JG et al. (2012) Structural and biophysical characterization of an antimicrobial peptide chimera comprised of lactoferricin and lactoferrampin. Biochim Biophys Acta 1818, 762-775.

 

Harrington JM, Shannon HS (1976) Incidence of tuberculosis, hepatitis, brucellosis, and shigellosis in British medical laboratory workers. Br Med J 1, 759-762.

 

He F (2011) Bradford protein assay. Bio-Protocol e45-e45.

 

He Y-M, Ma B-G (2016) Abundance and temperature dependency of protein-protein interaction revealed by interface structure analysis and stability evolution. Sci Rep 6, 1-8.

 

Hu K, Zhu Z, Mathahs MM et al. (2020) Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships. Drug Des Dev Ther 14, 757.

 

Ikeda M, Nozaki A, Sugiyama K et al. (2000) Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 66, 51-63.

 

Ikeda M, Sugiyama K, Tanaka T et al. (1998) Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Bioph Res Co 245, 549-553.

 

Inamullah I, Idrees M, Ahmed H et al. (2011) Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan. Virol J 8, 1-5.

 

Ishii K, Takamura N, Shinohara M et al. (2003) Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 25, 226-233.

 

Khan JA, Kumar P, Paramasivam M et al. (2001) Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 Å resolution and structural basis of its dual role. J Mol Biol 309, 751-761.

 

Kirkpatrick CH, Green I, Rich RR et al. (1971) Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J Infect Dis 124, 539-544.

 

Konishi M, Iwasa M, Araki J et al. (2006) Increased lipid peroxidation in patients with non‐alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8‐isoprostane. J Gastroen Hepatol 21, 1821-1825.

 

Krieger E, Nabuurs SB, Vriend G (2003) Homology modeling. Method Biochem Anal 44, 509-524.

 

Kwo PY, Badshah MB (2015) New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Tran 20, 235-241.

 

Lee J-K, Park S-C, Hahm K-S et al. (2014) A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice. Biomaterials 35, 1025-1039.

 

Levay PF, Viljoen M (1995) Lactoferrin: a general review. Haematologica 80, 252-267.

 

Li Y, Liu X, Zhu Y et al. (2013) Bioinformatic prediction of epitopes in the Emy162 antigen of Echinococcus multilocularis. Exp ther Med 6, 335-340.

 

Liberto MC, Marascio N (2022) Special Issue “Chronic HCV Infection: Clinical Advances and Eradication Perspectives”. Multidiscip resp med. pp. 359.

 

Lindahl E, Abraham M, Hess B et al. (2019) GROMACS 2019.4 source code. Zenodo.

 

Mangia A, Albanese AP, Bourliére M et al. (2021) Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. Adv Ther 38, 1397-1403.

 

Manns JM (2011) SDS‐polyacrylamide gel electrophoresis (SDS‐PAGE) of proteins. Current Prot Microbiol 22, A. 3M. 1-A. 3M. 13.

 

Miao M, Jing X, De Clercq E et al. (2020) Danoprevir for the treatment of hepatitis C virus infection: Design, development, and place in therapy. Drug Des Dev Ther 14, 2759.

 

Pirkhezranian Z, Tahmoorespur M, Daura X et al. (2020a) Interaction of camel Lactoferrin derived peptides with DNA: a molecular dynamics study. BMC Genomics 21, 1-14.

 

Pirkhezranian Z, Tahmoorespur M, Monhemi H et al. (2020b) Computational peptide engineering approach for selection the best engendered camel Lactoferrin-derive peptide with potency to interact with DNA. Int J Pept Res Ther 26, 2203-2212.

 

Redwan EM, El-Fakharany EM, Uversky VN et al. (2014) Screening the anti infectivity potentials of native N-and C-lobes derived from the camel lactoferrin against hepatitis C virus. BMC Complem Altern M 14, 1-16.

 

Redwan ERM, Tabll A (2007) Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J Immunoass Immunoch 28, 267-277.

 

Saleh NA, Elshemey WM (2017) Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors. Life Sci 187, 58-63.

 

Schwede T, Kopp J, Guex N et al. (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 31, 3381-3385.

 

Shen M, Zhou S, Li Y et al. (2013) Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Mol Biosyst 9, 361-374.

 

Shiffman ML, Long AG, James A et al. (2014) My treatment approach to chronic hepatitis C virus. In: Mayo Clinic Proceedings. Elsevier pp. 934-942.

 

Simmonds P, Bukh J, Combet C et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973.

 

Sinha M, Kaushik S, Kaur P et al. (2013) Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. Int J Pept 2013.

 

Smith DB, Pathirana S, Davidson F et al. (1997) The origin of hepatitis C virus genotypes. J Gen Virol 78, 321-328.

 

Solomon S, Wagner-Cardoso S, Smeaton L et al. (2021) A simple and safe approach to HCV treatment: findings from the A5360 (MINMON) trial. Top Med 38-38.

 

Tahmoorespur M, Azghandi M, Javadmanesh A et al. (2020) A novel chimeric anti-HCV peptide derived from camel lactoferrin and molecular level insight on its interaction with E2. Int J Pept Res Ther 26, 1593-1605.

 

Tanhaiean A, Azghandi M, Razmyar J et al. (2018) Recombinant production of a chimeric antimicrobial peptide in E. coli and assessment of its activity against some avian clinically isolated pathogens. Microb Pathogenesis 122, 73-78.

 

Tomita M (1994) The active peptide of lactoferrin. Acta Paediatr Japon 36, 585-591.

 

Ueno H, Sato T, Yamamoto S et al. (2006) Randomized, double‐blind, placebo‐controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci 97, 1105-1110.

 

van der Kraan MI, Groenink J, Nazmi K et al. (2004) Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25, 177-183.

 

van der Kraan MI, Nazmi K, Teeken A et al. (2005) Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exerts its candidacidal activity by a cluster of positively charged residues at the C-terminus in combination with a helix-facilitating N-terminal part. Biol Chem 137-142.

 

Van Der Spoel D, Lindahl E, Hess B et al. (2005) GROMACS: fast, flexible, and free.  26, 1701-1718.

 

Wang Z, Wang G (2004) APD: the antimicrobial peptide database. Nucleic Acids Res 32, D590-D592.

 

Watashi K, Shimotohno K (2007) Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti‐hepatitis C virus strategy. Rev Med Virol 17, 245-252.

 

Yadav O, Negi S (2020) Molecular dynamics simulations to see the effect of temperature and pressure change on the dynamics of protein. Int J Innov Phis 1, 24-29.

 

Yamauchi K, Tomita M, Giehl T et al. (1993) Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 61, 719-728.

 

Yun Z, Lara C, Johansson B et al. (1996) Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 49, 155-160.